Skip to main content
S. 5265 119th Congress Senate

USTRx Act

Official title: A bill to identify and take action against international trade practices of high income countries that unfairly exploit innovation by deviating from market-bas… Show full official titleShow less

Official title: A bill to identify and take action against international trade practices of high income countries that unfairly exploit innovation by deviating from market-based policies and unfairly exploit United States innovation, and for other purposes.

Introduced: August 5, 2026 Introduced by: Tim Sheehy Republican · Montana See on congress.gov
Foreign Trade and International Finance
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Aug 5, 2026
Introduced in Senate
Aug 5, 2026
Read twice and referred to the Committee on Finance.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now August 5, 2026

Read twice and referred to the Committee on Finance.

 Plain-English summary Congressional Research Service

Use Sovereignty To reduce Rx Act or the USTRx Act

This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers.

The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.

The bill also requires the USTR to submit to Congress a plan to respond to certain adverse acts, policies, or practices of high-income countries that are related to the trade of pharmaceutical products.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 2

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

 Cosponsors 2
All 2 Republican 2
R
Budd, Ted
North Carolina · Aug 5, 2026
 R
McCormick, David
Pennsylvania · Aug 5, 2026
Cite this page click to expand
APA
U.S. Congress. (2026). S. 5265: USTRx Act. 119th Congress. Open America. https://openamerica.io/bill/119-S-5265/
MLA
"S. 5265: USTRx Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-5265/.
Bluebook (legal)
S. 5265, 119th Cong. (2026), https://openamerica.io/bill/119-S-5265/.
Markdown link
[S. 5265: USTRx Act](https://openamerica.io/bill/119-S-5265/)
Report a problem